Padlock Therapeutics, a firm focused on the development of new treatment alternatives for autoimmune conditions, recently announced a collaboration with three different research institutes specialists in protein-argenine deiminase (PAD) enzymes and their effect on disease pathogenesis, including Systemic Lupus Erythematosus (SLE). Padlock will work directly with the University of…
Researchers at the Northwestern University Feinberg School of Medicine in Chicago recently characterized the risk of progression from discoid lupus erythematosus (DLE) to systemic lupus erythematosus (SLE) in children, and the disease phenotype. The study entitled “The natural history of pediatric-onset discoid lupus erythematosus” was published in…
In a new study entitled “TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus” researchers identified a new signaling pathway, mediated by the cytokine TWEAK and its receptor Fn14, which promotes chronic skin inflammation in a mouse model of cutaneous lupus erythematosus.
In a new study entitled “The receptor TREML4 amplifies TLR7-mediated signaling during antiviral responses and autoimmunity,” researchers identified a new molecule – TREML4 – that promotes TLR7-mediated release of inflammatory cytokines in systemic lupus erythematosus. The study was published in the journal Nature…
Researchers at The Feinstein Institute for Medical Research in Manhasset, New York recently published in the journal Lupus Science & Medicine their finding on two predictors of neuropsychological dysfunction in individuals with systemic lupus erythematosus (SLE). The study is entitled “Brain metabolism and…
Breakthroughs in new treatments for lupus may be useless if patients do not have access to innovative therapies as a consequence of their high costs or regulatory restrictions, a point raised the Lupus Foundation of America in a statement published on the organization’s website. The president and CEO of the Lupus…
In a recent study entitled “Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy,” researchers suggest two novel biomarkers for treatment outcome and renal disease in patients with Lupus nephritis. The study…
Mallinckrodt Pharmaceuticals recently announced two presentations during the 2015 Spring Clinical Meetings of the National Kidney Foundation (NKF) showing independent reports of positive results with the H.P. Acthar Gel in proteinuria’s remission. Proteinuria (excess of protein in urine) is linked to the nephrotic syndrome, which is characterized…
Global healthcare provider Eli Lilly and Company and the Korean pharmaceutical company Hanmi Pharmaceutical Co., Ltd. signed an exclusive license and collaboration agreement focused on accelerating the development process and commercialization of a potential treatment for autoimmune and other conditions, such as lupus. The oral drug was developed by Hanmi and is expected…
In a recent commentary titled “Dialogue: Vitamin D, statins and atherosclerotic progression in pediatric lupus” published in BMJ Lupus Science & Medicine, Gary Gilkeson from the Medical University of South Carolina and Sue Manzi from the Temple University School of Medicine discuss the…